24072-75-1Relevant articles and documents
Benzothiazole disperse dye monomer compound, synthesis method and application thereof
-
Paragraph 0076-0082, (2019/10/02)
The invention discloses a benzothiazole disperse dye monomer compound. The structure of the compound is shown as formula (I) in the specification, wherein X1 and X4 are hydrogen, halogen, nitro, methyl or methoxy independently; X2 and X3 are independently hydrogen, halogen, nitro, methyl, methoxy or cyano; X5 is hydrogen or C1-C4 alkoxy; X6 is hydrogen, C1-C4 alkyl, NHCOR1 or halogen, and R1 is C1-C4 alkyl. The invention also discloses a preparation method of the benzothiazole disperse dye monomer compound and application thereof in preparation of disperse dyes. According to the invention, a phenylthiourea compound is adopted as the starting raw material, and by means of condensation ring closure, diazotization and coupling, a disperse dye filter cake can be obtained. The obtained dispersedye has bright color, high coloring intensity, good dyeing reproducibility, and has excellent promotion performance, dye uptake, dyeing fastness, sunlight resistance and sublimation fastness.
IMIDAZO[2,1-B]THIAZOLE AND 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE DERIVATIVES USEFUL AS S100-INHIBITORS
-
Page/Page column 78; 79, (2016/04/09)
A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful for use in the treatment of cancer, an inflammatory disorder,an autoimmunity disorder or a neurodegenerative disorder.
Synthesis, cytotoxic evaluation, and in silico studies of substituted N-alkylbromo-benzothiazoles
Gill, Rupinder Kaur,Singh, Gagandeep,Sharma, Anuradha,Bedi,Saxena
, p. 4211 - 4222 (2013/09/02)
In efforts to develop a new class of anticancer agents with improved efficacy and selective action, a series of N-alkylbromo-benzothiazoles were synthesized and evaluated for in vitro cytotoxic activity against various human cancer cell lines such as lung (A-549), prostate (PC-3), leukemia (THP-1), and colon (Caco-2). They were found to be highly active against prostate (PC-3) and leukemia (THP-1) cancer cells, moderately active against colon (Caco-2) cancer cells and less active against lung (A-549) cancer cells. Of the 12 compounds, two (11d, 11j) exhibit IC50 values of ≤ 1 μM against leukemia (THP-1) cancer cell lines. Compound 11l showed significant cytotoxic activity against the PC-3 (IC50 = 0.6 μM), THP-1 (IC50 = 3 μM) and Caco-2 cell lines (IC50 = 9.9 μM), respectively. Docking study of the synthesized ligand was done on epidermal growth factor receptor using ArgusLab flexible docking, to determine their observed activity. Further QSAR investigations with stepwise multiple linear regression analysis were applied to find correlation between various physicochemical parameters and anticancer activity. The QSAR results showed that anticancer activity could be modeled with descriptors. The predictive ability of models was cross-validated by observation of the low residual activity values and adjusted coefficient of variation (radj2) obtained by leave-one-out technique.